ATE315939T1 - Verfahren zur prophylaxe oder kontrolle des katarakts - Google Patents

Verfahren zur prophylaxe oder kontrolle des katarakts

Info

Publication number
ATE315939T1
ATE315939T1 AT95900556T AT95900556T ATE315939T1 AT E315939 T1 ATE315939 T1 AT E315939T1 AT 95900556 T AT95900556 T AT 95900556T AT 95900556 T AT95900556 T AT 95900556T AT E315939 T1 ATE315939 T1 AT E315939T1
Authority
AT
Austria
Prior art keywords
cataract
prophylaxis
control
tgfbeta
relates
Prior art date
Application number
AT95900556T
Other languages
English (en)
Inventor
Johnston William Mcavoy
Coral Gwenda Chamberlain
Original Assignee
Univ Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sydney filed Critical Univ Sydney
Application granted granted Critical
Publication of ATE315939T1 publication Critical patent/ATE315939T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Prostheses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT95900556T 1993-11-19 1994-11-11 Verfahren zur prophylaxe oder kontrolle des katarakts ATE315939T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPM254093 1993-11-19

Publications (1)

Publication Number Publication Date
ATE315939T1 true ATE315939T1 (de) 2006-02-15

Family

ID=3777368

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95900556T ATE315939T1 (de) 1993-11-19 1994-11-11 Verfahren zur prophylaxe oder kontrolle des katarakts

Country Status (6)

Country Link
US (1) US20030130324A1 (de)
EP (1) EP0735895B1 (de)
JP (1) JPH09505057A (de)
AT (1) ATE315939T1 (de)
DE (1) DE69434617D1 (de)
WO (1) WO1995013827A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
WO1998016214A1 (en) * 1996-10-14 1998-04-23 Kissei Pharmaceutical Co., Ltd. Secondary cataract inhibitor
AUPO427196A0 (en) 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
NZ540885A (en) * 2002-12-20 2009-02-28 Chakshu Res Inc Ophthalmic formulation for the prevention and treatment of ocular conditions
US20060166879A1 (en) * 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
EP1740615B1 (de) 2004-03-31 2014-11-05 Genentech, Inc. Humanisierte anti-tgf-beta-antikörper
US8802651B2 (en) * 2004-06-30 2014-08-12 Abbott Medical Optics Inc. Hyaluronic acid in the enhancement of lens regeneration
US20080075756A1 (en) * 2004-06-30 2008-03-27 Advanced Medical Optics, Inc. Enhancement of lens regeneration using materials comprising polymers
US20060083732A1 (en) * 2004-06-30 2006-04-20 Arlene Gwon Hyaluronic acid in the enhancement of lens regeneration
CN101262887A (zh) * 2005-07-15 2008-09-10 视可舒研究公司 糖尿病的眼科并发症的预防和治疗
EP2010100B1 (de) * 2006-04-27 2018-11-28 Johnson & Johnson Surgical Vision, Inc. Materialien mit polysiloxan-polymeren zur verbesserten linsenregeneration
US8506944B2 (en) 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
HUE024146T2 (en) 2008-05-07 2016-02-29 Univ California Medical filling and enrichment of eye surface lubrication
EP2342340A1 (de) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna-interferenz bei hautindikationen
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
JP2013513622A (ja) 2009-12-14 2013-04-22 ユニバーシティ オブ マサチューセッツ 白内障及び老眼を阻害する方法
CN103200945B (zh) * 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
EP3560503B1 (de) 2010-03-24 2021-11-17 Phio Pharmaceuticals Corp. Rna-interferenz bei dermalen und fibrotischen erkrankungen
PE20151747A1 (es) 2013-03-14 2015-12-18 Univ Massachusetts Metodo para inhibir cataratas y presbicia
WO2015168108A2 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic targeting mdm2 or mycn
MX376641B (es) 2015-11-13 2025-03-07 Univ Massachusetts Moléculas bifuncionales que contienen peg para uso en la inhibición de cataratas y presbicia.

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61233622A (ja) * 1985-04-09 1986-10-17 Riken Vitamin Co Ltd 眼薬組成物
SU1500254A1 (ru) * 1986-01-10 1989-08-15 Ростовский медицинский институт Способ прогнозировани осложнений после операции экстракции стационарных травматических катаракт
US5401880A (en) * 1987-06-04 1995-03-28 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
WO1988009660A2 (en) * 1987-06-04 1988-12-15 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors
US5338545A (en) * 1987-06-04 1994-08-16 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
US5290813A (en) * 1987-06-04 1994-03-01 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors
FR2627078B1 (fr) * 1988-02-16 1994-03-18 Allergan Inc Dispositif oculaire
JPH02202818A (ja) * 1988-12-09 1990-08-10 Allergan Inc 白内障の治療における２―置換―チアゾリジン―４―カルボン酸類の用途
CA2066660C (en) * 1989-09-15 2002-07-30 Cary Reich Method for achieving epithelialization of synthetic lenses
FI921353A0 (fi) * 1989-09-29 1992-03-27 Jolla Cancer Res Found Inhibering av transformerande vaextfaktor b foer foerhindrande av ackumulation av extracellulaer matris.
TW224942B (de) * 1990-04-04 1994-06-11 Adka Ueno Kk
US5164187A (en) * 1990-04-05 1992-11-17 Norian Corporation Hydroxyapatite prosthesis coatings
ATE139683T1 (de) * 1990-12-03 1996-07-15 Adatomed Pharma Chiron Intraokulare künstliche augenlinse
IT1249047B (it) * 1991-02-21 1995-02-11 Zambon Spa Composizione farmaceutica per il trattamento della cataratta
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
IT1251838B (it) * 1991-09-20 1995-05-26 Lpb Ist Farm Uso della nimesulide nel trattamento della cataratta
AU669132B2 (en) * 1991-10-11 1996-05-30 Mark Cedric Gillies Treating ophthalmic fibrosis using interferon-alpha
WO1993009800A1 (en) * 1991-11-14 1993-05-27 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
JP3854307B2 (ja) * 1991-12-04 2006-12-06 ザ バーナム インスティテュート 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
WO1993019783A1 (en) * 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
WO1993021945A1 (en) * 1992-04-23 1993-11-11 The Regents Of The University Of California METHODS FOR TREATING VASCULAR DISORDERS BY INHIBITING THE ENDOTHELIN STIMULATORY ACTIVITY OF TGF$g(b)
JPH08502033A (ja) * 1992-07-08 1996-03-05 セルトリックス ファーマシューティカルズ，インコーポレイテッド ＴＧＦ−βを用いる眼疾患の治療方法
US5589464A (en) * 1992-09-01 1996-12-31 Allergan Use of 2-substituted-thiazolidine-4-carboxylic acids for treatment of cataract
US5847007A (en) * 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
DE69332026T2 (de) * 1992-10-29 2002-10-31 Celtrix Pharmaceuticals, Inc. Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel
WO1994010187A1 (en) * 1992-10-30 1994-05-11 Hsc Research And Development Limited Partnership COMPOSITIONS AND METHODS FOR MODIFYING THE REGULATORY ACTIVITY OF TGF-$g(b)
TW354762B (en) * 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
US5665770A (en) * 1993-11-05 1997-09-09 Gakko Hojin Kinki Daigaku Method for treatment of cataract with radical scavenger
WO2000001410A1 (en) * 1998-07-06 2000-01-13 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis

Also Published As

Publication number Publication date
DE69434617D1 (de) 2006-04-06
US20030130324A1 (en) 2003-07-10
EP0735895A4 (de) 2001-03-28
EP0735895B1 (de) 2006-01-18
EP0735895A1 (de) 1996-10-09
JPH09505057A (ja) 1997-05-20
WO1995013827A1 (en) 1995-05-26

Similar Documents

Publication Publication Date Title
ATE315939T1 (de) Verfahren zur prophylaxe oder kontrolle des katarakts
FI925756A0 (fi) Foerfarande foer rening av hyaluronsyra samt en ren hyaluronsyrafraktionavsedd foer oftalmisk anvaendning
UA41275C2 (uk) Гербіцидна композиція та спосіб контролю росту небажаних рослин
MX9206794A (es) Uso de acido salicilico para regular arrugas en lapiel y/o atrofia de la piel.
DE59807122D1 (de) Verwendung von fumarsäurederivaten zur behandlung von autoimmunerkrankungen
AU6008894A (en) Hypolipidaemic compounds
PL307527A1 (en) Crosslinked polymeric ammonium salts
DE69423782D1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
DE59507342D1 (de) Verfahren zur herstellung von heterologen bispezifischen antikörpern
GR3034407T3 (en) Skin tanning compositions
ES2138153T3 (es) Polieter poliamino metilen fosfonatos para el control de depositos con ph elevado.
ATE260051T1 (de) Verwendung von zusammensetzungen zur versorgung mit mineralien nach einer gastrotomie
DE69416166D1 (de) Verfahren zur regulierung von sialinsaeurederivaten in rekombinanten glykoproteinen
DE69112814D1 (de) Verfahren zur korrigierung und optimierung einer futterzusammensetzung.
DE69735224D1 (de) Verfahren zur Züchtung von Mikroorganismen die Methanol metabolisieren
ATE148074T1 (de) Verfahren zur kontrolle von schwingungen einer pendelnden last und vorrichtung zur durchführung des verfahrens
BG98761A (en) Substituted pyrroles
EP0591378A4 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie.
GB9410639D0 (en) Method of improving fertilization
DE69512903D1 (de) Für die vermeidung/begrenzung von mikrobiologisch beeinflusster korrosion und verfärbung verwendbare borate
DE69533807D1 (de) Verwendung des pilzes gliocadium catenulatun zur biologischen kontrolle von pflanzenkrankheiten
ATE101045T1 (de) Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen.
AU2001254634A1 (en) Use of neuregulin-beta as an indicator and/or target
DE69210286D1 (de) Behandlung von intraocularem Druck mit einer synergistischen Kombination
DE69013077D1 (de) Zusammensetzung zur Regulation des Pflanzenwachstums.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties